Sign up
Pharma Capital

OptiBiotix Health aiming to be big in Japan with latest deal

Following hard on the heels of a commercial deal covering the Baltic area, OptiBiotix Health plc (LON:OPTI) has signed an agreement that will see its breakthrough cholesterol-lowering bacteria strain distributed in Japan. Founder and CEO Stephen O'Hara talks Proactive London through OptiBiotix's last two RNS's and explains how they are inter-related. O'Hara also explains how he has an eye for an emerging trend and how this product, in his view, is one of those key moments.
For the UK group has negotiated an exclusive tie-up with the EIWA Trading Co for its LPLDL product. OptiBiotix will ship an agreed minimum volume of the cholesterol and blood pressure-reducing probiotic, Lactobacillus plantarum, which rises over the term of the three-year contract.


View full OPTI profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.